Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician-Controlled Mobile App
27 Septembre 2023 - 1:00PM
Augmedix, a healthcare technology company that delivers
industry-leading, ambient medical documentation and data solutions,
announced today the early access release of the newest product on
its platform, Augmedix Go, a clinician-controlled mobile app that
uses generative AI to instantaneously create a fully automated
draft medical note after each patient visit.
Augmedix Go harnesses proprietary natural
language processing (NLP), large language models (LLMs), and
structured data sets, key components of Augmedix’s tech stack. This
powerful technology is utilized in a thoughtful manner to ensure
comprehensive and highly accurate medical notes with appropriate
guardrails that safeguard against errors.
“As we pursue our goal of freeing clinicians
from administrative burdens to focus on patient care, we are proud
to deliver Augmedix Go. This fully automated product is an
important milestone highlighting how we are responsibly harnessing
the power of AI,” said Manny Krakaris, Chief Executive Officer of
Augmedix. “Augmedix Go is a highly scalable product that is priced
at a level to appeal to a broad base of healthcare systems.
Generative AI is a powerful tool, and we are committed to
engendering the trust of clinicians through a transparent user
interface that also provides clinicians controls to tailor medical
notes to their unique needs.”
Now available under early access, Augmedix Go
allows the clinician to see how the technology works in creating
the medical note through a simple and intuitive interface. This
innovative product offers a variety of features to support busy
healthcare clinicians throughout their clinic day, including
summaries of key medical events, reminders of unfinished notes, and
flexibility for post-visit dictation and text editing. The
technology offers output control through a multimodal interface and
can be utilized in both acute and ambulatory care settings.
“Augmedix was the first to bring to market the
practice of ambient medical documentation to the nation’s leading
health systems,” said Augmedix Founder, Director, and Chief
Strategy Officer Ian Shakil. “Building upon the success of our
full-service Augmedix Live and Augmedix Notes products, Augmedix Go
is unique in that it reimagines the clinician experience at scale.
This product serves as a prime example of the future of AI medical
documentation.”
Augmedix Go can be economically adopted and
implemented quickly across hospitals and health systems. Augmedix
Go allows clinicians immediate access to review, edit and approve
their medical notes, and can be integrated into leading electronic
health record (EHR) systems.
Augmedix Go will be showcased at the HLTH 2023
conference from October 8-11 in Las Vegas. Visit Augmedix's Booth
#3838 at HLTH to experience the future of AI medical documentation
with Augmedix Go.
Learn more at
https://augmedix.com/augmedix-go/.
About Augmedix
Augmedix (Nasdaq: AUGX) delivers
industry-leading, ambient medical documentation and data solutions
to healthcare systems, physician practices, hospitals, and
telemedicine practitioners.
Augmedix is on a mission to help clinicians and
patients form a human connection by seamlessly integrating our
technology at the point of care. Augmedix’s proprietary platform
digitizes the natural clinician-patient conversations, which are
converted into comprehensive medical notes and structured data in
real time. The company’s platform uses automatic speech recognition
and natural language processing, including large language models,
to generate accurate and timely medical notes that are transferred
into the EHR.
Augmedix’s products relieve clinicians of
administrative burden, in turn, reducing burnout, increasing
clinician efficiency and improving patient access. Through
Augmedix’s proprietary platform and bi-directional communication
channel, Augmedix is ideally suited to serve as the vehicle for
change at the point of care.
Augmedix is headquartered in San Francisco, CA,
with offices around the world. To learn more, visit
www.augmedix.com.
Contact Information
Investors:Matt Chesler, CFAFNK IR646-809-2183augx@fnkir.com
investors@augmedix.com
Media:Kaila GrafemanAugmedixpr@augmedix.com
Forward-Looking Statements
This press release contains “forward-looking
statements” that involve a number of risks and uncertainties. Such
forward-looking statements include, without limitation, statements
regarding the intended benefits, capabilities and scalability of
Augmedix Go; statements regarding the pricing of Augmedix Go;
statements regarding Augmedix Go redefining efficiency and serving
as a prime example of the future of AI medical documentation; and
statements regarding the timing for the rollout of additional
Augmedix Go specialties. Actual results could differ materially
from those stated or implied in forward-looking statements due to a
number of factors, including but not limited to, risks detailed in
our most recent Form 10-K filed with the U.S. Securities and
Exchange Commission on April 17, 2023, as well as other documents
that may be filed by us from time to time with the U.S. Securities
and Exchange Commission. The forward-looking statements included in
this press release represent our views as of the date of this press
release. We undertake no intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. These forward-looking
statements should not be relied upon as representing our views as
of any date subsequent to the date of this press release.
Augmedix (NASDAQ:AUGX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Augmedix (NASDAQ:AUGX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024